Travere Therapeutics

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Travere Therapeutics reports robust earnings, eyes market expansion opportunities

Travere Therapeutics is on a solid financial footing with promising drug launches and clinical advancements. While facing regulatory and competitive challenges, the company's strategic focus on market expansion and product utilization presents significant growth opportunities. With a strong cash position and ongoing clinical developments, Travere is well-positioned for future success.

Travere Therapeutics reports strong Q1 performance amidst FILSPARI launch

Travere Therapeutics' Q1 performance was driven by strong FILSPARI sales and positive physician adoption.
Despite challenges in FSGS and HCU programs, regulatory flexibility and patient community evolution present opportunities.
Physician interest in FILSPARI data and payer coverage quality are key strengths for the successful launch.
Monitoring metrics and upcoming study readouts offer avenues for growth and optimization in rare disease treatments.

Travere Therapeutics reports strong Q2 performance and growth opportunities

Travere Therapeutics showcased strong performance with revenue growth and positive clinical results across key programs.
The company's strategic focus on core pipeline programs and divestment of non-core assets has bolstered its financial position.
Challenges include competitive dynamics, regulatory uncertainties, and the need for disciplined spending amidst growth opportunities.
Overall, Travere is well-positioned for future growth with promising pipeline programs and a focus on market expansion.

Travere Therapeutics reports strong Q3 performance and strategic advancements

Travere Therapeutics showcased strong operational and financial performance in Q3 2023, with advancements in key programs and positive regulatory engagements.
The company's strategic focus on rare disease treatments, patient education efforts, and regulatory alignment position it well for future growth.
Challenges in revenue forecasting, market positioning, and evolving treatment landscapes highlight areas for ongoing strategic focus and adaptation.
Opportunities in market expansion, revenue growth, program advancements, and patient engagement present avenues for continued success and impact.

Travere Therapeutics reports strong revenue growth and strategic advancements

Travere Therapeutics had a successful year with strong revenue growth and progress in key treatments
Filspari's performance in IgAN drove demand and revenue, positioning the company for further growth
Challenges include the DUPLEX study results and low innovation in the prescriber base
Opportunities lie in sNDA submissions, ongoing studies, and potential for full approval and broader label

Travere Therapeutics excels in Q1 with FILSPARI market success

Travere Therapeutics showcased strong performance and financial stability in Q1 2024, driven by FILSPARI's successful commercial launch and positive patient outcomes.
The company's focus on market adoption, regulatory milestones, and engagement strategies positions it for continued growth and potential inclusion in treatment guidelines.
Challenges in inventory management, regulatory compliance, and strategic alignment with stakeholders need to be addressed to capitalize on growth opportunities and maintain market leadership.

Travere Therapeutics excels in Q2 2024, poised for growth

Travere Therapeutics delivered a strong performance in Q2 2024, driven by FILSPARI's growth and positive regulatory developments.
While facing challenges in regulatory processes and market expansion, the company's solid financial position and ongoing initiatives position it well for future success.
Opportunities for growth abound through potential approvals, global expansion, and advancements in drug development programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Travere Therapeutics' sparsentan received full FDA approval for IgA nephropathy, showing long-term kidney function preservation and significant market growth, with $35mn in 3Q24 revenues. Despite setbacks in FSGS trials, ongoing studies and FDA involvement suggest potential future approval, bolstered by proteinuria reduction as a validated surrogate endpoint. Financially, TVTX faces high operating expenses and cash runway concerns but aims to extend runway to 2028 through restructuring and secondary offerings.

Travere Therapeutics: Cautiously Bullish Based On Improving Revenue

Dublin, Dec. 18, 2024 (GLOBE NEWSWIRE) -- The "Homocystinuria - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering. This report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Homocystinuria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Homocystinuria Therapeutics Market Research 2024: Insights About 3+ Companies and 3+ Pipeline Drugs Featuring Travere Therapeutics and Syntis Bio

NEW YORK, NY / ACCESSWIRE / November 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in December:

Travere Therapeutics to Present at Upcoming Investor Conferences

Kidney disease leader Travere Therapeutics is pulling back to a key support level on the stock market today. The post Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level appeared first on Investor's Business Daily.

Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level

SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that on November 10, 2024, the Compensation Committee of its Board of Directors granted inducement equity grants to six new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 24,400 shares of its common stock. These inducement RSUs are subject to the terms of Travere's 2018 Equity Incentive Plan (“2018 Plan”) but were granted outside of the 2018 Plan and were granted as inducements material to the new employees entering into employment with Travere in accordance with Nasdaq Listing Rule 5635(c)(4).

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Natera

Tenet Healthcare

The healthcare sector is vast and includes everything from massive legacy companies including UnitedHealth Group Inc. NYSE: UNH and McKesson Corp. NYSE: MCK to tiny upstart pharmaceuticals firms. Investors looking to explore this sector thus have a choice about whether to focus on established companies with steadier business operations but, perhaps, less of a possibility of future growth, or on smaller firms that offer a higher-risk, higher-reward prospect.

3 Under-the-Radar Healthcare Companies

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of $16.00 per share. All of the shares are being sold by Travere. The gross proceeds from the offering are expected to be $125.0 million, before deducting the underwriting discounts and commissions and offering expenses. The offering is expected to close on November 12, 2024, subject to customary closing conditions. In addition, Travere has granted the underwriters for the offering a 30-day option to purchase up to an additional 1,171,875 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Travere Therapeutics Announces Pricing of Public Offering of Common Stock

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it intends to offer and sell, in an underwritten public offering and subject to market and other conditions, shares of its common stock. All of the shares are being offered by Travere. In addition, Travere intends to grant the underwriters for the offering a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Travere Therapeutics Announces Proposed Public Offering of Common Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q3 2024 Earnings Conference Call October 31, 2024 8:30 AM ET Company Participants Nivi Nehra - Vice President of Corporate Communications and Investor Relations Eric Dube - President and CEO Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - CFO Bill Rote - Senior Vice President of Research & Development Conference Call Participants Anupam Rama - JPMorgan Greg Wiesner - TD Cowen Joe Thomas - Scotiabank Laura Chico - Wedbush Securities Sadia Rahman - Wells Fargo Operator Good morning, and welcome to the Travere Therapeutics' Third Quarter 2024 Financial Results Conference Call. Today's call is being recorded.

Travere Therapeutics, Inc. (TVTX) Q3 2024 Earnings Call Transcript

The headline numbers for Travere (TVTX) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Travere (TVTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

Travere Therapeutics (TVTX) came out with a quarterly loss of $0.70 per share in line with the Zacks Consensus Estimate. This compares to loss of $1.17 per share a year ago.

Travere Therapeutics (TVTX) Reports Q3 Loss, Tops Revenue Estimates

Nearly 60% of patients with IgAN in the SPARTAN Study achieved complete remission when using FILSPARI as first-line treatment SPARTACUS Study, PROTECT open-label extension, and real-world evidence presentations highlight initial safety and efficacy data of FILSPARI in combination treatment in IgAN Late-breaking presentation demonstrates sparsentan delivered rapid and sustained proteinuria reduction, and long-term kidney health benefits in a subset of patients with genetic, often treatment resistant, FSGS SAN DIEGO, Oct. 26, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX), presented new data further demonstrating the clinical benefit of FILSPARI (sparsentan) in IgA nephropathy (IgAN) and reinforcing its potential in focal segmental glomerulosclerosis (FSGS) at the American Society of Nephrology (ASN) Kidney Week 2024. “The data presented at ASN provided additional evidence that FILSPARI is effective across all subgroups of IgAN patients studied to-date, and that it achieved significant levels of complete remission when used in newly diagnosed patients.

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024

The mean of analysts' price targets for Travere (TVTX) points to a 26.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 26.27% Upside in Travere (TVTX): Can the Stock Really Move This High?

SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2024 financial results on Thursday, October 31, 2024, before the open of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 8:30 a.m. ET.

Travere Therapeutics to Report Third Quarter 2024 Financial Results

SAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) and CSL Vifor today announced that Swissmedic has granted temporary marketing authorization for FILSPARI for the treatment of adults with primary IgA nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). “FILSPARI targets damage directly in the kidney and offers patients a convenient, once daily, oral, non-immunosuppressive treatment that can provide superior results compared to maximally dosed irbesartan, supporting replacing their RASi,” said Eric Dube, Ph.D.

Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy

CSL Ltd

Temporary marketing authorization is based on statistically significant and clinically meaningful results from the phase-III PROTECT trial ST. GALLEN, Switzerland and SAN DIEGO, Oct. 17, 2024 /PRNewswire/ -- CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that Swissmedic has granted temporary marketing authorization for FILSPARI for the treatment of adults with primary IgA nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g).

CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

NEW YORK CITY, NY / ACCESSWIRE / October 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Connect

NEW YORK, NY / ACCESSWIRE / October 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere Therapeutics, Inc.") (NASDAQ:TVTX) concerning possible violations of federal securities laws. Travere issued a press release on September 26, 2024, "announc[ing] a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).

Travere Therapeutics, Inc. (TVTX) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates

Data presentations highlight the results for FILSPARI ® (sparsentan), the only approved kidney-targeted medicine for IgA nephropathy, when used as a first-line treatment, and in combination with other therapies Late-breaking presentation details outcomes of sparsentan's effect in a subgroup of high-risk patients with genetic focal segmental glomerulosclerosis SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present 11 abstracts, including one late-breaking abstract at the upcoming American Society of Nephrology (ASN) Kidney Week 2024 in San Diego, CA, October 23-27, 2024. Presentations will include new data from the SPARTAN Study highlighting efficacy and safety results of FILSPARI (sparsentan) in IgA nephropathy (IgAN) when used as a first-line treatment in newly diagnosed IgAN patients, an analysis from the PROTECT Study examining the clinical benefit of FILSPARI in IgAN regardless of participants' baseline proteinuria, as well as patient-reported outcomes from the PROTECT and DUPLEX Studies.

Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2024

NEW YORK CITY, NY / ACCESSWIRE / October 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.

Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Stockholders to Inquire about Securities Investigation

NEW YORK, NY / ACCESSWIRE / October 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere Therapeutics, Inc.") (NASDAQ:TVTX) concerning possible violations of federal securities laws. Travere issued a press release on September 26, 2024, "announc[ing] a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).

Investors who lost money on Travere Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigation - TVTX

NEW YORK, Oct. 13, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. (“Travere” or “the Company”) (NASDAQ: TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.

TVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm

NEW YORK CITY, NY / ACCESSWIRE / October 13, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation

NEW YORK CITY, NY / ACCESSWIRE / October 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Reach Out

News for Travere Therapeutics Stock (TVTX)